CHU de Brest — Brest, France

Public research footprint of CHU de Brest, compiled from the ClinicalTrials.gov public registry.

256

Registered studies

110

Active

Recruiting now

113

Completed

Stopped or withdrawn

Most-studied conditions

Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor… · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer · Advanced Non-small Cell Lung Cancer, HER2 Mutation

Recently updated registry entries

NCT05663866 — Premedication to Reduce Amivantamab Associated Infusion Related Reactions (Active Not Recruiting)
NCT06741969 — Nipocalimab in Moderate to Severe Sjogren's Disease (Active Not Recruiting)
NCT05702034 — A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at CHU de Brest?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.